Company Profile
Disc Medicine Stock Price, News & Catalysts
- Ticker:
- IRON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
78.47 USD (-5.78%)
Close
Last updated: November 5, 2026
2.6B USD
Market cap
Why the stock is moving
Following the latest company update, “Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update”, IRON closed down 5.78% at $78.47 on Nov 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Hematology Drug Development
Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease.
Bitopertin in EPP
Bitopertin is being evaluated in the Phase 3 APOLLO trial for erythropoietic protoporphyria, a disorder caused by accumulation of phototoxic protoporphyrin. The program has completed enrollment and is intended to support a response to an earlier FDA complete response letter.
DISC-0974 for Anemia
DISC-0974 is an investigational anti-hemojuvelin therapy designed to suppress hepcidin and improve iron availability. It is being studied in the Phase 2 RALLY-MF trial for anemia of myelofibrosis and in a separate Phase 2 study for anemia associated with inflammatory bowel disease.
DISC-3405
DISC-3405 is a monoclonal antibody targeting transferrin receptor 1. The candidate is in Phase 2 development for polycythemia vera and Phase 1b development for sickle cell disease, extending Disc’s approach to disorders of red-cell production and function.
Future catalysts
- Updated RESTORE-PV data and initial Phase 1b DISC-3405 data in sickle cell disease by year-end 2026.
- FDA feedback on pivotal development of selcodebart in myelofibrosis-related anemia by year-end 2026.
- Resubmission of the bitopertin NDA for erythropoietic protoporphyria by year-end 2026.
- FDA decision on the resubmitted bitopertin application by mid-2027.
- Topline RESTORE-PV data and initiation of pivotal development for DISC-3405 in polycythemia vera in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Disc Medicine (IRON)?
Disc Medicine (IRON) most recently closed at 78.47 USD, a -5.78% move versus the previous session.
What is the market cap of Disc Medicine (IRON)?
Disc Medicine currently has a market capitalization of 2.6B USD on BioPharmSignal.
What does Disc Medicine do?
Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO trial for...
On which exchange is IRON stock listed?
Disc Medicine (IRON) is associated with NASDAQ, United States, Biopharma.
What is DISC-0974?
DISC-0974 for Anemia DISC-0974 is an investigational anti-hemojuvelin therapy designed to suppress hepcidin and improve iron availability.
Which conditions is Disc Medicine targeting with DISC-0974?
Disc Medicine is associated with hematology based on its company overview and current catalyst commentary.
How does Disc Medicine describe recent progress with DISC-0974?
Updated RESTORE-PV data and initial Phase 1b DISC-3405 data in sickle cell disease by year-end 2026. FDA feedback on pivotal development of selcodebart in myelofibrosis-related anemia by year-end 2026. Resubmission of the bitopertin NDA for erythropoietic protoporphyria by year-end 2026. FDA decision on the resubmitted bitopertin application by mid-2027....
What is RALLY-MF?
It is being studied in the Phase 2 RALLY-MF trial for anemia of myelofibrosis and in a separate Phase 2 study for anemia associated with inflammatory bowel disease.